For research use only. Not for therapeutic Use.
Lusvertikimab（Cat No.:I042190）is an investigational monoclonal antibody that targets IL-33 (interleukin-33), a cytokine involved in immune system regulation and inflammation. IL-33 is implicated in various inflammatory and autoimmune diseases, including asthma, allergic conditions, and cardiovascular diseases. By blocking IL-33, lusvertikimab aims to reduce inflammation and modulate immune responses, potentially providing therapeutic benefits in conditions driven by excessive IL-33 signaling. It is being studied in clinical trials for its potential to treat asthma, atopic dermatitis, and other inflammatory disorders, with a focus on improving patient outcomes and symptom control.
| CAS Number | 2375835-91-7 |
| Purity | ≥95% |
